An update on TroVax for the treatment of progressive castration-resistant prostate cancer - Wikidata - wikimedia - TriplyDB

An update on TroVax for the treatment of progressive castration-resistant prostate cancer

An update on TroVax for the treatment of progressive castration-resistant prostate cancer

http://www.wikidata.org/entity/Q35050205

about

Proposed mechanisms of action for prostate cancer vaccines.Update on prostate cancer vaccines

P2860

Q35174754-27BF8EC2-2546-4032-96A2-ACC3F0AE32BC Q36169608-87874BE5-B267-4890-8DDB-3DE3AEEF09B6

P2860

An update on TroVax for the treatment of progressive castration-resistant prostate cancer

http://www.wikidata.org/entity/Q35050205

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

An update on TroVax for the treatment of progressive castration-resistant prostate cancer

@ast

An update on TroVax for the treatment of progressive castration-resistant prostate cancer

@en

type

label

An update on TroVax for the treatment of progressive castration-resistant prostate cancer

@ast

An update on TroVax for the treatment of progressive castration-resistant prostate cancer

@en

prefLabel

An update on TroVax for the treatment of progressive castration-resistant prostate cancer

@ast

An update on TroVax for the treatment of progressive castration-resistant prostate cancer

@en

P1433

Q35050205-710DC9B0-E9B7-4313-95C5-8B5EFD2A39F6

P1476

Q35050205-0459CF47-9A5E-4B0B-A93A-3134286F7C42

P2093

Q35050205-81153D7B-6CF0-4E8E-A426-62E3D5FB41EB

Q35050205-ADDA8F98-CBB1-4CE9-AA27-0BD334E0F984

P2860

Q35050205-00EDB1AC-D27E-4675-8786-567E6D292C56

Q35050205-01BB2DC9-AF5B-4EA3-BB7B-2F5664ACC87A

Q35050205-08D734ED-3292-4B08-ACCE-38DE1E2B5487

Q35050205-142D38B8-E2A4-48F0-910E-5A4C7274D31F

Q35050205-2857202F-DFF5-4606-95C4-EC2600520325

Q35050205-2A4CD9E3-024E-4B53-8F5B-68C60F584D76

Q35050205-3092A2B4-060E-4D50-93FA-C60228F01750

Q35050205-3444D8A1-4FDE-451A-B24C-125CEBEBCEAD

Q35050205-3CD35E62-6647-41B7-9B2C-00E7BDDAF638

Q35050205-41114A07-E8BB-4345-BA1A-6B6D1FA5BB55

P304

Q35050205-26864FAA-8B0E-4026-889D-C0146BA9A039

P31

Q35050205-2A8CC37E-9DAE-4608-A4B7-9DF4C1A812AE

P356

Q35050205-FA1CEC88-5DA7-45E3-AA55-3E7ABD982E0D

P407

Q35050205-53EDF693-FCF0-4FF3-AF17-56B1E5671895

P478

Q35050205-D5FF82A9-6261-4D37-8212-D048EA1BC9DE

P50

Q35050205-F5CD392A-9837-478C-A033-C75A7D0D68BD

P577

Q35050205-6173584E-805A-4595-984B-B6CFFAF9E4B2

P5875

Q35050205-7F245E12-2962-4329-AF60-314A2634B009

P698

Q35050205-986E4B6E-CCF4-4713-8D09-1337E00AFD18

P932

Q35050205-C8E249AE-85D3-4523-A4FB-C2E7FB0007E9

P356

P1433

OncoTargets and Therapy

P1476

An update on TroVax for the treatment of progressive castration-resistant prostate cancer

@en

P2093

Kalyan Latchamsetty

http://www.w3.org/2001/XMLSchema#string

Michael Abern

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

P304

33-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S14271

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Howard L. Kaufman

P577

2011-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51236865

http://www.w3.org/2001/XMLSchema#string

P698

21691576

http://www.w3.org/2001/XMLSchema#string

P932

3116792

http://www.w3.org/2001/XMLSchema#string